I-Mab to Present Latest Givastomig Data at Major Oncology Conference

I-Mab to Present Latest Givastomig Data at Major Oncology Conference

I-Mab, a global biotechnology corporation specializing in precision immuno-oncology, announced that it will share updated results from its Phase 1 study of givastomig at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The event will take place from October 22 to 26 in Boston, Massachusetts.

Givastomig, designed as a targeted therapy for advanced gastroesophageal carcinoma (GEC), was tested as a monotherapy in heavily pre-treated patients. The new data will be presented in a “short-talk” session by Dr. Samuel J. Klempner of Massachusetts General Hospital. I-Mab's strategy involves advancing givastomig into randomized Phase 2 trials in first-line gastric cancer patients, with plans to pair the drug with standard treatments, aiming to benefit patients expressing a wide range of Claudin 18.2 levels. This approach is based on promising results regarding monotherapy activity and safety from earlier-stage studies.

About Givastomig

Givastomig (TJ033721 / ABL111) is a novel bispecific antibody that targets Claudin 18.2, a protein commonly expressed in certain gastrointestinal tumors. By conditionally activating T cells through the 4-1BB pathway within the tumor environment, givastomig potentially delivers a strong anti-tumor effect with minimized risk of side effects typical for other 4-1BB treatments. Its development focuses on first-line metastatic gastric cancer and may expand to other gastrointestinal cancers showing Claudin 18.2 positivity. Givastomig's innovation lies in its dual targeting, resulting from a collaboration between I-Mab and ABL Bio, with shared global rights outside Greater China and South Korea.

I-Mab’s Oncology Pipeline

The corporation is further developing a differentiated portfolio targeting high-need cancers. Its leading asset, givastomig, offers potential best-in-class performance among treatments designed for Claudin 18.2-positive gastric cancers. Additionally, I-Mab is working with ABL Bio on ragistomig, another bispecific antibody that integrates PD-L1 tumor engagement with conditional T cell activation for improved therapy in solid tumors.

Conference Presentation Details

  • Title: Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma
  • Session: Bispecifics/T-cell Engagers
  • Speaker: Dr. Samuel J. Klempner, Massachusetts General Hospital
  • Date & Time: Thursday, October 23, 6:20 – 6:35 PM ET
  • Location: Hynes Convention Center, Boston, MA

Considering Investment Risks in Biotech Development

For investors assessing corporation investment opportunities in the biotech sector, it is important to conduct thorough investment analysis and manage portfolio risk. Drug development is subject to extensive regulatory hurdles and market competition, as highlighted in I-Mab’s forward-looking statements and risk disclosures. Potential investors should review all related risks and uncertainties before making any investment decisions in performance stocks within this sector.

This content is for informational purposes only and does not constitute financial advice.

Back to news
topBuild my Portfolio for Freedown